Novo Nordisk’s AMAZE 1 Obesity Trial Signals Next Wave in Weight-Loss Pipeline

Novo Nordisk (NVO) announced an update on their ongoing clinical study.

Study Overview: Novo Nordisk has launched AMAZE 1, a Phase 3 trial titled “Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1).” The study aims to see how well a new once-weekly drug, NNC0487-0111, helps people with excess body weight lose weight and how safe it is over time. For investors, this is another key step in Novo Nordisk’s push to expand its obesity franchise beyond current blockbusters, with potential to support long-term growth if results are strong.

Intervention/Treatment: The trial tests NNC0487-0111, a prescription drug given as a once-weekly injection under the skin using a pre-filled pen. Participants will receive one of four dose levels of NNC0487-0111 or a placebo injection that contains no active medicine. The goal is to show that NNC0487-0111 can deliver meaningful, sustained weight loss when combined with a lower-calorie diet and more physical activity.

Study Design: AMAZE 1 is an interventional study where participants are randomly assigned by chance to either NNC0487-0111 or placebo. It uses a parallel design, meaning people stay in their assigned group for the whole trial. The study is quadruple-masked, so participants, doctors, trial staff, and outcome assessors do not know who is getting the active drug or placebo. The main purpose is to test whether NNC0487-0111 is an effective and safe treatment for obesity.

Study Timeline: The study was first submitted on January 13, 2026, and the latest update on ClinicalTrials was also filed on January 13, 2026, with status listed as “not yet recruiting.” Primary completion and full completion dates have not yet been posted, but as a Phase 3 obesity trial, investors should expect a multi-year timeline from first patient dosing to full data readout. The current update signals that the program is moving from planning toward active enrollment.

Market Implications: For Novo Nordisk (NVO), AMAZE 1 reinforces a clear strategy to deepen its obesity pipeline and defend its lead in the fast-growing weight-loss market. A successful outcome could extend the company’s product life cycle beyond existing GLP-1 drugs and support premium valuation multiples tied to obesity and metabolic health. In the near term, the trial’s “not yet recruiting” status is more of a pipeline validation than an earnings driver, but it should support positive longer-term sentiment among growth-focused investors. Competitors such as Eli Lilly, Pfizer, and emerging biotech players are all racing to develop next-generation obesity drugs; Novo Nordisk’s ability to move multiple late-stage assets in parallel helps protect share and bargaining power with payers. Investors should watch for future updates on recruitment progress, interim data, and any safety signals that could affect both NVO and the broader obesity segment.

The AMAZE 1 study is active in setup and recently updated, with full details and future changes available on the ClinicalTrials.gov portal under NCT07339423.

To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.